Corcept Therapeutics | CORT - Selling And Administration Expenses


Corcept Therapeutics reported $142.04M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Alaunos Therapeutics USD 424K 23K Jun/2026
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Ardelyx USD 101.44M 827K Jun/2026
Aurora Cannabis CAD 40.89M 515K Jun/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Canopy Growth CAD 33.99M 2.83M Jun/2026
Corcept Therapeutics USD 142.04M 14.86M Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
J&J USD 6.25B 168M Sep/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.86B 25M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.08B 163M Sep/2026
Novartis USD 3.08B 58M Sep/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 950.8M 858.99M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026